Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.
Preprint
- 16 August 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
A recent randomized controlled trial demonstrated that treatment with CD38 monoclonal antibody felzartamab suppressed antibody-mediated rejection (ABMR) in kidney transplant patients but with recurrence post-treatment in some patients. The present study examined the molecular effects of 6-months of felzartamab treatment on biopsies from the trial using genome-wide microarray analysis, comparing pre-treatment, end-of-treatment (24 week) and post-treatment (week 52) biopsies from 10 felzartamab and 10 placebo patients. Felzartamab reduced molecular ABMR activity scores in all 9 patients with baseline ABMR activity, selectively suppressing interferon gamma-inducible and natural killer cell transcripts, with minimal effect on ABMR-induced endothelial transcripts. Suppression was often incomplete when ABMR activity was intense, and molecular recurrence was nearly universal by week 52. However, we also found that felzartamab had parenchymal benefits at week 52, slowing the trajectories of molecular injury scores beyond the treatment period, suggesting that suppression of ABMR activity could potentially slow future progression to kidney failure.Keywords
All Related Versions
- Version 1, 2024-08-16, Research Square
- Published version: Nature Medicine, 31 (5), 1668.
This publication has 33 references indexed in Scilit:
- Subthreshold rejection activity in many kidney transplants currently classified as having no rejectionAmerican Journal of Transplantation, 2024
- A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionNew England Journal of Medicine, 2024
- Epithelial cell states associated with kidney and allograft injuryNature Reviews Nephrology, 2024
- Translating B cell immunology to the treatment of antibody-mediated allograft rejectionNature Reviews Nephrology, 2024
- An atlas of healthy and injured cell states and niches in the human kidneyNature, 2023
- Daratumumab Use Prior to Kidney Transplant and T Cell–Mediated Rejection: A Case ReportAmerican Journal of Kidney Diseases, 2023
- clusterProfiler 4.0: A universal enrichment tool for interpreting omics dataThe Innovation, 2021
- Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) SystemThe Journal of Heart and Lung Transplantation, 2017
- Molecular assessment of disease states in kidney transplant biopsy samplesNature Reviews Nephrology, 2016
- Antibody-mediated rejection, T cell–mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsiesKidney International, 2014